{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T21:48:40Z","timestamp":1782078520485,"version":"3.54.5"},"reference-count":71,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Li-Fraumeni syndrome, caused by germline TP53 pathogenic sequence variants (PSVs), is among the most penetrant hereditary cancer syndromes. With broader genetic testing and improved survivorship, more women with TP53 PSVs now seek reproductive and hormonal guidance throughout their lifespan. Yet, no evidence-based framework currently exists to support women\u2019s health care in this population. In this review, we searched the available literature and found an absence of data regarding contraception, fertility preservation, pregnancy, and menopause, resulting in inconsistent counseling and both under- and overtreatment. Drawing on analogies from other high-risk cancer syndromes and our multidisciplinary clinical experience, we present interim suggestions centered on shared decision-making, individualized hormonal management, and avoiding unnecessary interventions. These findings underscore the need for prospective studies and international registries to establish evidence-based and equitable women\u2019s health care for women with TP53 PSVs.<\/jats:p>","DOI":"10.1093\/oncolo\/oyag212","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:52:48Z","timestamp":1781178768000},"source":"Crossref","is-referenced-by-count":0,"title":["Women\u2019s health across the reproductive lifespan in women with germline\n                    <i>TP53<\/i>\n                    pathogenic variants: a clinical perspective"],"prefix":"10.1093","volume":"31","author":[{"given":"Naama","family":"Halpern","sequence":"first","affiliation":[{"name":"The Jusidman Cancer Center, Sheba Medical Center , Ramat Gan 5265601,","place":["Israel"]},{"name":"Gray Faculty of Medical and Health Sciences, School of Medicine, Tel-Aviv University , Tel Aviv-Yafo, 6997801,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinat","family":"Bernstein-Molho","sequence":"additional","affiliation":[{"name":"The Jusidman Cancer Center, Sheba Medical Center , Ramat Gan 5265601,","place":["Israel"]},{"name":"Gray Faculty of Medical and Health Sciences, School of Medicine, Tel-Aviv University , Tel Aviv-Yafo, 6997801,","place":["Israel"]},{"name":"The Suzanne Levy-Gertner Oncogenetics Unit, Danek Gertner Institute of Human Genetics, Sheba Medical Center , Ramat Gan 5265601,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehudit","family":"Peerless","sequence":"additional","affiliation":[{"name":"The Jusidman Cancer Center, Sheba Medical Center , Ramat Gan 5265601,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Kventsel","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hemato-Oncology, Edmond and Lilly Safra Children\u2019s Hospital and Cancer Research Center, Sheba Medical Center , Ramat Gan 5265601,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehavit","family":"Frenkel","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hemato-Oncology, Edmond and Lilly Safra Children\u2019s Hospital and Cancer Research Center, Sheba Medical Center , Ramat Gan 5265601,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2533-6972","authenticated-orcid":false,"given":"Yossi","family":"Mizrachi","sequence":"additional","affiliation":[{"name":"Gray Faculty of Medical and Health Sciences, School of Medicine, Tel-Aviv University , Tel Aviv-Yafo, 6997801,","place":["Israel"]},{"name":"Fertility Unit, Edith Wolfson Medical Centre, and Gray Faculty of Medical Sciences, Tel-Aviv University , Tel Aviv-Yafo 5822012,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagit","family":"Shani","sequence":"additional","affiliation":[{"name":"Preimplantation Genetic Diagnosis Center, Danek Gertner Institute of Human Genetics, Sheba Medical Center , Ramat Gan 6997801,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7979-1655","authenticated-orcid":false,"given":"Myriam","family":"Safrai","sequence":"additional","affiliation":[{"name":"Gray Faculty of Medical and Health Sciences, School of Medicine, Tel-Aviv University , Tel Aviv-Yafo, 6997801,","place":["Israel"]},{"name":"Fertility Unit, Edith Wolfson Medical Centre, and Gray Faculty of Medical Sciences, Tel-Aviv University , Tel Aviv-Yafo 5822012,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"2026062117364501700_oyag212-B1","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1126\/science.1978757","article-title":"Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms","volume":"250","author":"Malkin","year":"1990","journal-title":"Science (1979)"},{"key":"2026062117364501700_oyag212-B2","doi-asserted-by":"publisher","first-page":"100242","DOI":"10.1016\/j.xhgg.2023.100242","article-title":"Genome-first approach of the prevalence and cancer phenotypes of pathogenic or likely pathogenic germline TP53 variants","volume":"5","author":"de Andrade","year":"2024","journal-title":"HGG Adv"},{"key":"2026062117364501700_oyag212-B3","first-page":"5358","article-title":"A cancer family syndrome in twenty-four kindreds","volume":"48","author":"Li","year":"1988","journal-title":"Cancer Res"},{"key":"2026062117364501700_oyag212-B4","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1200\/JCO.2014.59.5728","article-title":"Revisiting Li-Fraumeni syndrome from TP53 mutation carriers","volume":"33","author":"Bougeard","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026062117364501700_oyag212-B5","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.1002\/cncr.30248","article-title":"Risks of first and subsequent cancers among TP53 mutation carriers in the national cancer institute Li-Fraumeni syndrome cohort","volume":"122","author":"Mai","year":"2016","journal-title":"Cancer"},{"key":"2026062117364501700_oyag212-B6","doi-asserted-by":"publisher","first-page":"e2300453","DOI":"10.1200\/PO.23.00453","article-title":"Cancer risks associated with TP53 pathogenic variants: maximum likelihood analysis of extended pedigrees for diagnosis of first cancers beyond the Li-Fraumeni syndrome spectrum","volume":"8","author":"Fortuno","year":"2024","journal-title":"JCO Precis Oncol."},{"key":"2026062117364501700_oyag212-B7","doi-asserted-by":"publisher","first-page":"dju055","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"JNCI J Natl Cancer Inst"},{"key":"2026062117364501700_oyag212-B8","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/s41379-020-0610-4","article-title":"Histopathologic features of breast cancer in Li-Fraumeni syndrome","volume":"34","author":"Kuba","year":"2021","journal-title":"Mod Pathol"},{"key":"2026062117364501700_oyag212-B9","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1093\/jnci\/djae074","article-title":"TP53-associated early breast cancer: new observations from a large cohort","volume":"116","author":"Sandoval","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"2026062117364501700_oyag212-B10","author":"Hereditary Cancer Syndromes and Risk Assessment"},{"key":"2026062117364501700_oyag212-B11","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/jnci\/djy001","article-title":"Differences in TP53 mutation carrier phenotypes emerge from panel-based testing","volume":"110","author":"Rana","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"2026062117364501700_oyag212-B12","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1001\/jamaoncol.2021.4398","article-title":"Analysis of the Li-Fraumeni spectrum based on an international germline TP53 variant data set: an international agency for research on cancer TP53 database analysis","volume":"7","author":"Kratz","year":"2021","journal-title":"JAMA Oncol"},{"key":"2026062117364501700_oyag212-B13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13073-025-01429-5","article-title":"TP53 germline testing and hereditary cancer: how somatic events and clinical criteria affect variant detection rate","volume":"17","author":"Rofes","year":"2025","journal-title":"Genome Med"},{"key":"2026062117364501700_oyag212-B14","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S1470-2045(16)30249-2","article-title":"Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study","volume":"17","author":"Villani","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026062117364501700_oyag212-B15","doi-asserted-by":"publisher","first-page":"e38\u201345","DOI":"10.1158\/1078-0432.CCR-17-0408","article-title":"Cancer screening recommendations for individuals with Li-Fraumeni syndrome","volume":"23","author":"Kratz","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026062117364501700_oyag212-B16","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41431-020-0638-4","article-title":"Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes","volume":"28","author":"Frebourg","year":"2020","journal-title":"Eur J Hum Genet EJHG"},{"key":"2026062117364501700_oyag212-B17","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1158\/1078-0432.CCR-24-3301","article-title":"Update on cancer screening recommendations for individuals with Li\u2013fraumeni syndrome","volume":"31","author":"Achatz","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026062117364501700_oyag212-B18","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.6004\/jnccn.2023.0051","article-title":"NCCN guidelines\u00ae insights: genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2024: featured updates to the NCCN guidelines","volume":"21","author":"Daly","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"2026062117364501700_oyag212-B19","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1056\/NEJMoa1700732","article-title":"Contemporary hormonal contraception and the risk of breast cancer","volume":"377","author":"M\u00f8rch","year":"2017","journal-title":"N Engl J Med"},{"key":"2026062117364501700_oyag212-B20","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1093\/jnci\/94.23.1773","article-title":"Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"94","author":"Narod","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"2026062117364501700_oyag212-B21","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1093\/carcin\/bgab107","article-title":"Oral contraceptives and risk of breast cancer and ovarian cancer in women with a BRCA1 or BRCA2 mutation: a meta-analysis of observational studies","volume":"43","author":"Park","year":"2022","journal-title":"Carcinogenesis"},{"key":"2026062117364501700_oyag212-B22","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1200\/JCO.24.00176","article-title":"Hormonal contraception and breast cancer risk for carriers of germline mutations in BRCA1 and BRCA2","volume":"43","author":"Phillips","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026062117364501700_oyag212-B23","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1016\/j.ejca.2010.04.018","article-title":"Oral contraceptive use and breast or ovarian cancer risk in BRCA1\/2 carriers: a meta-analysis","volume":"46","author":"Iodice","year":"2010","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"2026062117364501700_oyag212-B24","doi-asserted-by":"publisher","first-page":"4774","DOI":"10.3390\/cancers14194774","article-title":"Oral contraceptive use and breast cancer risk for BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis of case-control studies","volume":"14","author":"Bara\u0144ska","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026062117364501700_oyag212-B25","doi-asserted-by":"publisher","first-page":"441","DOI":"10.31083\/j.ejgo.2021.03.2281","article-title":"Oral contraception use in BRCA gene mutation carriers: information for counselling in routine clinical practice","volume":"42","year":"2021","journal-title":"Eur J Gynaecol Oncol"},{"key":"2026062117364501700_oyag212-B26","doi-asserted-by":"publisher","first-page":"1006.e1-1006","DOI":"10.1016\/j.jaad.2023.12.017","article-title":"Guidelines of care for the management of acne vulgaris","volume":"90","author":"Reynolds","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2026062117364501700_oyag212-B27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ejca.2019.05.005","article-title":"Reproductive factors associated with breast cancer risk in Li-Fraumeni syndrome","volume":"116","author":"Khincha","year":"2019","journal-title":"Eur J Cancer"},{"key":"2026062117364501700_oyag212-B28","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1097\/AOG.0000000000001248","article-title":"Successful oocyte cryopreservation in Reproductive-Aged cancer survivors","volume":"127","author":"Druckenmiller","year":"2016","journal-title":"Obstet Gynecol"},{"key":"2026062117364501700_oyag212-B29","doi-asserted-by":"publisher","first-page":"600","DOI":"10.3389\/fendo.2019.00600","article-title":"Oocyte cryopreservation in oncological patients: eighteen years experience of a tertiary care referral center","volume":"10","author":"Specchia","year":"2019","journal-title":"Front Endocrinol"},{"key":"2026062117364501700_oyag212-B30","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.fertnstert.2015.11.027","article-title":"Oocyte vitrification as an efficient option for elective fertility preservation","volume":"105","author":"Cobo","year":"2016","journal-title":"Fertil Steril"},{"key":"2026062117364501700_oyag212-B31","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1093\/humrep\/dex008","article-title":"Predicting the likelihood of live birth for elective oocyte cryopreservation: a counseling tool for physicians and patients","volume":"32","author":"Goldman","year":"2017","journal-title":"Hum Reprod Oxf Engl"},{"key":"2026062117364501700_oyag212-B32","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.ygyno.2019.06.017","article-title":"Reproductive and hormonal considerations in women at increased risk for hereditary gynecologic cancers: Society of Gynecologic Oncology and American Society for Reproductive Medicine evidence-based review","volume":"155","author":"Chen","year":"2019","journal-title":"Gynecol Oncol"},{"key":"2026062117364501700_oyag212-B33","doi-asserted-by":"publisher","first-page":"e261332","DOI":"10.1001\/jamanetworkopen.2026.1332","article-title":"Cancer incidence in women after medically assisted reproduction","volume":"9","author":"Vajdic","year":"2026","journal-title":"JAMA Netw Open"},{"key":"2026062117364501700_oyag212-B34","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.fertnstert.2016.08.035","article-title":"Fertility drugs and cancer: a guideline","volume":"106","author":"Practice Committee of the American Society for Reproductive Medicine. Electronic Address: Practice Committee of the American Society for Reproductive Medicine","year":"2016","journal-title":"Fertil Steril"},{"key":"2026062117364501700_oyag212-B35","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1093\/humrep\/deac035","article-title":"Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis","volume":"37","author":"Arecco","year":"2022","journal-title":"Hum Reprod Oxf Engl"},{"key":"2026062117364501700_oyag212-B36","doi-asserted-by":"publisher","first-page":"115434","DOI":"10.1016\/j.ejca.2025.115434","article-title":"Assisted reproductive technology in young BRCA carriers with a pregnancy after breast cancer: an international cohort study","volume":"222","author":"Magaton","year":"2025","journal-title":"Eur J Cancer"},{"key":"2026062117364501700_oyag212-B37","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.fertnstert.2024.10.014","article-title":"Long-term safety of controlled ovarian stimulation for fertility preservation before chemotherapy treatment in patients with breast cancer","volume":"123","author":"Shapira","year":"2025","journal-title":"Fertil Steril"},{"key":"2026062117364501700_oyag212-B38","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.rbmo.2021.08.003","article-title":"Fertility preservation for women with breast cancer before chemotherapy: a systematic review and meta-analysis","volume":"44","author":"Chen","year":"2022","journal-title":"Reprod Biomed Online"},{"key":"2026062117364501700_oyag212-B39","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1200\/JCO-24-02782","article-title":"Fertility preservation in people with cancer: ASCO guideline update","volume":"43","author":"Su","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026062117364501700_oyag212-B40","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1002\/ijgo.16170","article-title":"Fertility stimulation protocols in women with cancer","volume":"169","author":"Purandare","year":"2025","journal-title":"Int J Gynaecol Obstet"},{"key":"2026062117364501700_oyag212-B41","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1210\/jc.2006-0962","article-title":"Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy","volume":"91","author":"Oktay","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2026062117364501700_oyag212-B42","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1093\/humrep\/dex027","article-title":"The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review","volume":"32","author":"Rodgers","year":"2017","journal-title":"Hum Reprod"},{"key":"2026062117364501700_oyag212-B43","doi-asserted-by":"publisher","first-page":"7976","DOI":"10.1038\/s41467-025-62894-5","article-title":"Peripheral blood DNA methylation predicts the early onset of primary tumor in TP53 mutation carriers","volume":"16","author":"Subasri","year":"2025","journal-title":"Nat Commun"},{"key":"2026062117364501700_oyag212-B44","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMra1614676","article-title":"Fertility preservation in women","volume":"377","author":"Donnez","year":"2017","journal-title":"N Engl J Med"},{"key":"2026062117364501700_oyag212-B45","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10689-022-00293-1","article-title":"Preimplantation genetic testing in patients with genetic susceptibility to cancer","volume":"22","author":"Villy","year":"2023","journal-title":"Fam Cancer"},{"key":"2026062117364501700_oyag212-B46","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/s1472-6483(10)61953-0","article-title":"Celebrating preimplantation genetic diagnosis of p53 mutations in Li-Fraumeni syndrome","volume":"3","author":"Simpson","year":"2001","journal-title":"Reprod Biomed Online"},{"key":"2026062117364501700_oyag212-B47","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.fertnstert.2023.03.003","article-title":"Indications and management of preimplantation genetic testing for monogenic conditions: a committee opinion","volume":"120","author":"Practice Committee and Genetic Counseling Professional Group of the American Society for Reproductive Medicine, American Society for Reproductive Medicine, Washington, D.C. Electronic Address: asrm@Asrm.org","year":"2023","journal-title":"Fertil Steril"},{"key":"2026062117364501700_oyag212-B48","doi-asserted-by":"publisher","first-page":"e35943","DOI":"10.1002\/cncr.35943","article-title":"Transmission ratio distortion of germline TP53 variants in Li-Fraumeni syndrome families","volume":"131","author":"Halpern","year":"2025","journal-title":"Cancer"},{"key":"2026062117364501700_oyag212-B49","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1136\/jmg.29.6.398","article-title":"Use of oocytes from anonymous, matched, fertile donors for prevention of heritable genetic diseases","volume":"29","author":"Van Voorhis","year":"1992","journal-title":"J Med Genet"},{"key":"2026062117364501700_oyag212-B50","doi-asserted-by":"publisher","first-page":"103604","DOI":"10.1016\/j.critrevonc.2022.103604","article-title":"Fertility counseling in women with hereditary cancer syndromes","volume":"171","author":"Somigliana","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026062117364501700_oyag212-B51","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.fertnstert.2021.01.045","article-title":"Guidance regarding gamete and embryo donation","volume":"15","author":"Practice Committee of the American Society for Reproductive Medicine and the Practice Committee for the Society for Assisted Reproductive Technology. Electronic Address: ASRM@Asrm.org","year":"2021","journal-title":"Fertil Steril"},{"key":"2026062117364501700_oyag212-B52","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1200\/JCO.21.00535","article-title":"Pregnancy after breast cancer: a systematic review and meta-analysis","volume":"39","author":"Lambertini","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026062117364501700_oyag212-B53","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1002\/cncr.34371","article-title":"Survival outcomes following pregnancy or assisted reproductive technologies after breast cancer: a population-based study","volume":"128","author":"Rauh-Hain","year":"2022","journal-title":"Cancer"},{"key":"2026062117364501700_oyag212-B54","author":"Breast Imaging During Pregnancy"},{"key":"2026062117364501700_oyag212-B55","doi-asserted-by":"publisher","first-page":"110189","DOI":"10.1016\/j.clinimag.2024.110189","article-title":"Breast cancer screening in BRCA1\/2 pathogenic sequence variant carriers during pregnancy and lactation","volume":"11","author":"Sorin","year":"2024","journal-title":"Clin Imaging"},{"key":"2026062117364501700_oyag212-B56","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.annonc.2023.08.001","article-title":"ESMO expert consensus statements on the management of breast cancer during pregnancy (PrBC)","volume":"34","author":"Loibl","year":"2023","journal-title":"Ann Oncol"},{"key":"2026062117364501700_oyag212-B57","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1080\/13697137.2022.2035711","article-title":"Menopausal hormone therapy: why we should no longer be afraid of the breast cancer risk","volume":"25","author":"Tan","year":"2022","journal-title":"Climacteric J Int Menopause Soc"},{"key":"2026062117364501700_oyag212-B58","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1001\/jama.2022.24140","article-title":"Management of menopausal symptoms: a review","volume":"329","author":"Crandall","year":"2023","journal-title":"JAMA"},{"key":"2026062117364501700_oyag212-B59","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/GME.0000000000002028","article-title":"The 2022 hormone therapy position statement of the North American menopause society","volume":"29","author":"Faubion","year":"2022","journal-title":"Menopause"},{"key":"2026062117364501700_oyag212-B60","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1001\/jama.2020.9482","article-title":"Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women\u2019s health initiative randomized clinical trials","volume":"324","author":"Chlebowski","year":"2020","journal-title":"JAMA"},{"key":"2026062117364501700_oyag212-B61","doi-asserted-by":"publisher","first-page":"m3873","DOI":"10.1136\/bmj.m3873","article-title":"Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases","volume":"371","author":"Vinogradova","year":"2020","journal-title":"BMJ"},{"key":"2026062117364501700_oyag212-B62","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.annonc.2024.10.824","article-title":"Estrogens and breast cancer","volume":"36","author":"Kim","year":"2025","journal-title":"Ann Oncol"},{"key":"2026062117364501700_oyag212-B63","first-page":"CD000402","article-title":"Hormone therapy in postmenopausal women and risk of endometrial hyperplasia or endometrial cancer\u2014Kim, D\u20142025","volume":"10","author":"Kim","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"2026062117364501700_oyag212-B64","doi-asserted-by":"publisher","first-page":"108894","DOI":"10.1016\/j.maturitas.2026.108894","article-title":"Menopausal hormone therapy and breast cancer: Balancing risks and benefits","volume":"208","author":"Bollam","year":"2026","journal-title":"Maturitas"},{"key":"2026062117364501700_oyag212-B65","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0140-6736(19)31709-X","article-title":"Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence","volume":"394","author":"Collaborative Group on Hormonal Factors in Breast Cancer","year":"2019","journal-title":"Lancet"},{"key":"2026062117364501700_oyag212-B66","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ejca.2021.02.007","article-title":"Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy","volume":"148","author":"Michaelson-Cohen","year":"2021","journal-title":"Eur J Cancer"},{"key":"2026062117364501700_oyag212-B67","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1001\/jamainternmed.2025.4421","article-title":"Elinzanetant for the treatment of vasomotor symptoms associated with menopause: a phase 3 randomized clinical trial","volume":"185","author":"Panay","year":"2025","journal-title":"JAMA Intern Med"},{"key":"2026062117364501700_oyag212-B68","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.maturitas.2015.01.003","article-title":"Perspective on prescribing conjugated estrogens\/bazedoxifene for estrogen-deficiency symptoms of menopause: a practical guide","volume":"80","author":"Palacios","year":"2015","journal-title":"Maturitas"},{"key":"2026062117364501700_oyag212-B69","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/01.AOG.0000441353.20693.78","article-title":"Management of menopausal symptoms","volume":"123","author":"ACOG Practice Bulletin No141","year":"2014","journal-title":"Obstet Gynecol"},{"key":"2026062117364501700_oyag212-B70","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1097\/AOG.0000000000001592","article-title":"Salpingo-oophorectomy at the time of benign hysterectomy: a systematic review","volume":"128","author":"Evans","year":"2016","journal-title":"Obstet Gynecol"},{"key":"2026062117364501700_oyag212-B71","doi-asserted-by":"publisher","first-page":"e067528","DOI":"10.1136\/bmj-2021-067528","article-title":"Association of bilateral salpingo-oophorectomy with all cause and cause specific mortality: population based cohort study","volume":"375","author":"Cusimano","year":"2021","journal-title":"BMJ"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag212\/68513819\/oyag212.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag212\/68513819\/oyag212.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag212\/68513819\/oyag212.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T21:36:54Z","timestamp":1782077814000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag212\/8706460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":71,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag212","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,6,6]]},"article-number":"oyag212"}}